GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
Reason given: The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.
Key facts
- Where
- Augusta, Baltimore, Bellaire, Bellevue, Beverly Hills, Boston, Chesterfield, Cincinnati, Dallas, Fort Myers, Great Neck, Indianapolis, Lemont, Marietta, Morgantown, New York, Palo Alto, Philadelphia, Phoenix, Portland, Reno, Rochester, Salt Lake City, Silverdale, Spokane, St. Petersburg, The Woodlands, Tucson, Vauxhall, West Des Moines, Willow Park, and Winston-Salem, United StatesSee the 33 sites
Where in United States
- Southeast Retina CenterAugusta, United StatesNo longer taking part
- Johns Hopkins University School Of MedicineBaltimore, United StatesNo longer taking part
- The Retina Care CenterBaltimore, United StatesNo longer taking part
- Retina Consultants of Houston-TMCBellaire, United StatesNo longer taking part
- Proliance Retina (formally known as Vitreoretinal Associates of Washington)Bellevue, United StatesNo longer taking part
- Retina-Vitreous Associates Medical GroupBeverly Hills, United StatesNo longer taking part
- Ophthalamic Consultants of Boston (OCB)Boston, United StatesNo longer taking part
- Pepose Vision InstituteChesterfield, United StatesNo longer taking part
- Cincinnati Eye InstituteCincinnati, United StatesNo longer taking part
- Retina Foundation of the SouthwestDallas, United StatesNo longer taking part
- Retina Health CenterFort Myers, United StatesNo longer taking part
- Long Island Vitreoretinal ConsultantsGreat Neck, United StatesNo longer taking part
- Midwest Eye Institute NorthsideIndianapolis, United StatesNo longer taking part
- University Retina Macula Associates PCLemont, United StatesNo longer taking part
- Georgia Retina PCMarietta, United StatesNo longer taking part
- West Virginia UniversityMorgantown, United StatesNo longer taking part
- Columbia University Medical CenterNew York, United StatesNo longer taking part
- Byers Eye Institute at StanfordPalo Alto, United StatesNo longer taking part
- Mid Atlantic RetinaPhiladelphia, United StatesNo longer taking part
- Retinal Research Institute (retina consultants of AZ)Phoenix, United StatesNo longer taking part
- Casey Eye Institute - OHSUPortland, United StatesNo longer taking part
- Sierra Eye AssociatesReno, United StatesNo longer taking part
- Retina Association of Western New YorkRochester, United StatesNo longer taking part
- Retina Associates of UtahSalt Lake City, United StatesNo longer taking part
- Retina Center NorthwestSilverdale, United StatesNo longer taking part
- Spokane Eye Clinical ResearchSpokane, United StatesNo longer taking part
- Retina Vitreous Associates of FloridaSt. Petersburg, United StatesNo longer taking part
- Retina Consultants of HoustonThe Woodlands, United StatesNo longer taking part
- Retina Centers PCTucson, United StatesNo longer taking part
- New Jersey Retina Research FoundationVauxhall, United StatesNo longer taking part
- Wolfe Eye ClinicWest Des Moines, United StatesNo longer taking part
- Strategic Clinical Research LLCWillow Park, United StatesNo longer taking part
- Wake Forest Baptist Medical Center - Wake Forest University School of MedicineWinston-Salem, United StatesNo longer taking part
Trial details
- Who runs it
- Gyroscope Therapeutics Limited
- Trial code
- NCT03894020
- Record updated
- 30 October 2024
- Original description
An observational study to evaluate the natural progression of dry AMD in genetically defined subjectsRead full original descriptionShow less
A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
Inclusion: Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD); BCVA of 40 letters or better using ETDRS charts.
Exclusion: Participation in another research study involving an investigational product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline OR received a gene/cell therapy at any time previously; Significant ocular or non-ocular disease that would impact the subject's ability to participate in the study; Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic retinopathy.